Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Cancer Biol Ther
2015 Jan 01;164:518-27. doi: 10.1080/15384047.2015.1016661.
Show Gene links
Show Anatomy links
Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.
Krishnamurthy N
,
Liu L
,
Xiong X
,
Zhang J
,
Montano MM
.
???displayArticle.abstract???
Triple negative breast cancer cell lines have been reported to be resistant to the cyotoxic effects of temozolomide (TMZ). We have shown previously that a novel protein, human homolog of Xenopus gene which Prevents Mitotic Catastrophe (hPMC2) has a role in the repair of estrogen-induced abasic sites. Our present study provides evidence that downregulation of hPMC2 in MDA-MB-231 and MDA-MB-468 breast cancer cells treated with temozolomide (TMZ) decreases cell survival. This increased sensitivity to TMZ is associated with an increase in number of apurinic/apyrimidinic (AP) sites in the DNA. We also show that treatment with another alkylating agent, BCNU, results in an increase in AP sites and decrease in cell survival. Quantification of western blot analyses and immunofluorescence experiments reveal that treatment of hPMC2 downregulated cells with TMZ results in an increase in γ-H2AX levels, suggesting an increase in double strand DNA breaks. The enhancement of DNA double strand breaks in TMZ treated cells upon downregulation of hPCM2 is also revealed by the comet assay. Overall, we provide evidence that downregulation of hPMC2 in breast cancer cells increases cytotoxicity of alkylating agents, representing a novel mechanism of treatment for breast cancer. Our data thus has important clinical implications in the management of breast cancer and brings forth potentially new therapeutic strategies.
Alarcon,
Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA.
2001, Pubmed
Alarcon,
Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA.
2001,
Pubmed
Atamna,
A method for detecting abasic sites in living cells: age-dependent changes in base excision repair.
2000,
Pubmed
Biasco,
Treatment of brain metastases of malignant melanoma with temozolomide.
2001,
Pubmed
Chaney,
DNA repair: enzymatic mechanisms and relevance to drug response.
1996,
Pubmed
Cheng,
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
2005,
Pubmed
Clemons,
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
2005,
Pubmed
Colleoni,
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
2010,
Pubmed
Dinnes,
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
2002,
Pubmed
Fishel,
Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.
2007,
Pubmed
Fong,
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
2009,
Pubmed
Jacot,
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.
2010,
Pubmed
Ketchart,
HEXIM1 is a critical determinant of the response to tamoxifen.
2011,
Pubmed
Krishnamurthy,
The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sites.
2011,
Pubmed
,
Xenbase
Lindahl,
Quality control by DNA repair.
1999,
Pubmed
Liu,
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
1999,
Pubmed
Liu,
Base excision repair as a therapeutic target in colon cancer.
2002,
Pubmed
Liu,
Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts.
2003,
Pubmed
Liuzzi,
A new approach to the study of the base-excision repair pathway using methoxyamine.
1985,
Pubmed
Middleton,
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
2000,
Pubmed
Montano,
The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.
1997,
Pubmed
Mortusewicz,
Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells.
2007,
Pubmed
Nakamura,
Highly sensitive apurinic/apyrimidinic site assay can detect spontaneous and chemically induced depurination under physiological conditions.
1998,
Pubmed
Ogba,
HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb.
2008,
Pubmed
Parkin,
Global cancer statistics, 2002.
2005,
Pubmed
Patil,
Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid).
2010,
Pubmed
Ratnam,
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
2007,
Pubmed
Rinne,
Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells.
2004,
Pubmed
Rogakou,
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.
1998,
Pubmed
Rosa,
Processing in vitro of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed in vivo.
1991,
Pubmed
Sobol,
Mammalian DNA beta-polymerase in base excision repair of alkylation damage.
2001,
Pubmed
Sripathy,
hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen.
2008,
Pubmed
Stachelek,
Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation.
2010,
Pubmed
Tentori,
Pharmacological strategies to increase the antitumor activity of methylating agents.
2002,
Pubmed
Tentori,
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
2003,
Pubmed
Trivedi,
Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide.
2008,
Pubmed
Trivedi,
The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.
2005,
Pubmed
Trudeau,
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
2006,
Pubmed
Weydert,
Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth.
2008,
Pubmed
Wilson,
Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA.
1995,
Pubmed
Wood,
Human DNA repair genes.
2001,
Pubmed
Wood,
DNA repair in eukaryotes.
1996,
Pubmed
Yan,
Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.
2007,
Pubmed
Yan,
Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU.
2005,
Pubmed
van Brussel,
A phase II study of temozolomide in hormone-refractory prostate cancer.
2000,
Pubmed
